RATE OF MICROSCOPIC COLITIS AND CYTOKINE LEVELS IN PATIENTS WITH IRRITABLE BOWEL SYNDROME

Basit Öğe Kaydı
dc.contributor.authorUcmak, Feyzullah
dc.contributor.authorGoral, Vedat
dc.contributor.authorFirat, Ugur
dc.contributor.authorMete, Nuriye
dc.date.accessioned2024-04-24T17:45:07Z
dc.date.available2024-04-24T17:45:07Z
dc.date.issued2015
dc.departmentDicle Üniversitesien_US
dc.description.abstractAims: The aim of this study is to determine the rate of microscopic colitis (MC) among patients diagnosed as Irritable Bowel Syndrome (IBS) in accordance with Roma III criteria and to investigate the correlation of cytokine levels with the type of IBS and presence of MC. Methodology: A total of Eighty-nine patients who were diagnosed with IBS based on Rome Ill diagnostic criteria were included in this study. Biopsies taken from caecum, ascending colon, transverse colon, descending colon and rectosigmoid region during colonoscopy were put in separate tubes and histopathologically examined. In addition, serum TNF-alpha, IL-1 beta and IL-6 levels were determined in peripheral blood samples of patients. Results: The frequency of MC was higher in the study groups compared to the general population (22.5% and 20.4% in IBS-D and IBS-C groups, respectively). Specimens taken from caecum, ascending colon, transverse colon and descending colon were more likely to lead to the diagnosis of MC compared to those taken from rectrosigmoid region (p<0.001). No significant difference was found between presence of MC and IL-1 beta, IL-6 and TNF-alpha levels. In addition, TNF-a levels were significantly higher in the IBS-C group (p= 0.013). Conclusion: Rate of MC in IBS patients is higher than the rate in normal population. In IBS patients, biopsy samples obtained solely from rectosigmoid area is not sufficient to preclude MC diagnosis. No difference exists between IBS patients with and without MC in terms of cytokine levels.en_US
dc.description.sponsorshipAli Raif Medicine Industry Inc.; Deva Holding Medicine Groupen_US
dc.description.sponsorshipAli Raif Medicine Industry Inc. and Deva Holding Medicine Group contributed to the funding of this study.en_US
dc.identifier.endpage108en_US
dc.identifier.issn0393-6384
dc.identifier.issue1en_US
dc.identifier.startpage103en_US
dc.identifier.urihttps://hdl.handle.net/11468/22425
dc.identifier.volume31en_US
dc.identifier.wosWOS:000346319200016
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.language.isoenen_US
dc.publisherCarbone Editoreen_US
dc.relation.ispartofActa Medica Mediterranea
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectIrritable Bowel Syndromeen_US
dc.subjectMicroscopic Colitisen_US
dc.subjectCytokinesen_US
dc.titleRATE OF MICROSCOPIC COLITIS AND CYTOKINE LEVELS IN PATIENTS WITH IRRITABLE BOWEL SYNDROMEen_US
dc.titleRATE OF MICROSCOPIC COLITIS AND CYTOKINE LEVELS IN PATIENTS WITH IRRITABLE BOWEL SYNDROME
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu